1918 Influenza Virus-Neutralizing Antibodies from Individuals Born 1960-1990

1960-1990 年出生者的 1918 年流感病毒中和抗体

基本信息

项目摘要

DESCRIPTION (provided by applicant): Current vaccines induce the generation of B cells that secrete neutralizing antibodies targeting the influenza virus hemagglutinin (HA), but these antibody responses are quite strain-specific. However, several monoclonal antibodies have been described that exhibit relatively broad cross-neutralizing activity. In collaboration with Dr. James Crowe (Vanderbilt University), we recently described a human monoclonal antibody from a 1918 pandemic survivor which neutralized not only the 1918 virus but also human H1N1 viruses from 1943 and 1977. These data suggest that cross-reactive epitopes on different HA molecules exist; however, responses to such epitopes clearly do not predominate the human immune response to infection or vaccination. Our long term goal is to understand what determines the magnitude and specificity of human antibody responses to strain-specific versus broadly neutralizing HA epitopes, as this may facilitate development of more broadly protective vaccines. Toward this goal, we seek to characterize monoclonal antibodies from individuals born well after 1918 that neutralize the 1918 pandemic influenza virus. We other have separately detected high titer 1918-neutralizing antibodies in the sera of approximately 13 percent of individuals born well after 1918. Given that these individuals have not been exposed to the 1918 virus, the origin of these anti-1918 antibodies is unclear, but presumably they were elicited by exposure to other influenza virus strains. We hypothesize that some of these 1918-neutralzing antibodies will exhibit unusual cross-reactivity towards different H1 molecules. Therefore, we hope that defining the specificity of monoclonal 1918-neutralizing antibodies from these individuals will suggest strategies to elicit broad H1-neutralizing antibodies. We will (1) Develop efficient methods to isolate, from individuals born well after the 1918 influenza pandemic, 1918 hemagglutinin-specific human B cells and produce anti-1918 human monoclonal antibodies; and (2) Characterize 1918-specific human monoclonal antibodies from individuals born well after the 1918 influenza pandemic.. PUBLIC HEALTH RELEVANCE: Seasonal influenza continues to cause substantial morbidity and mortality annually in the United States, and the possible emergence of a new, pandemic influenza virus is a continuing concern. Completion of this project will identify the epitopes on the 1918 pandemic influenza virus HA recognized by antibodies from relatively young individuals. It is hoped this information will provide insight into new, more effective vaccine strategies.
描述(由申请方提供):目前的疫苗诱导产生B细胞,该细胞分泌靶向流感病毒血凝素(HA)的中和抗体,但这些抗体应答具有很强的毒株特异性。然而,已经描述了几种表现出相对广泛的交叉中和活性的单克隆抗体。在与James Crowe博士(范德比尔特大学)的合作中,我们最近描述了一种来自1918年大流行幸存者的人单克隆抗体,该抗体不仅中和了1918年的病毒,还中和了1943年和1977年的人H1N1病毒。这些数据表明,在不同的HA分子上存在交叉反应性表位;然而,对这些表位的应答显然并不主导对感染或疫苗接种的人免疫应答。我们的长期目标是了解是什么决定了人类抗体对菌株特异性HA表位与广泛中和HA表位的反应的幅度和特异性,因为这可能有助于开发更广泛的保护性疫苗。为了实现这一目标,我们试图从1918年以后出生的个体中鉴定出中和1918年大流行性流感病毒的单克隆抗体。另外,我们在1918年以后出生的大约13%的人的血清中分别检测到高滴度的1918中和抗体。鉴于这些人没有接触过1918年病毒,这些抗1918抗体的来源尚不清楚,但推测它们是通过接触其他流感病毒株引起的。我们假设这些1918-中和抗体中的一些将对不同的H1分子表现出不寻常的交叉反应性。因此,我们希望确定这些个体的单克隆1918中和抗体的特异性将建议引发广泛的H1中和抗体的策略。我们将(1)开发有效的方法,从1918年流感大流行后出生的个体中分离1918血凝素特异性人B细胞,并产生抗1918人单克隆抗体;(2)表征1918年流感大流行后出生的个体中1918特异性人单克隆抗体。 公共卫生关系:在美国,季节性流感每年继续导致大量的发病率和死亡率,并且新的大流行性流感病毒的可能出现是一个持续的问题。该项目的完成将确定1918年大流行性流感病毒HA上的表位,这些表位可被相对年轻的个体的抗体识别。希望这些信息将为新的、更有效的疫苗策略提供见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher F Basler其他文献

Sensing RNA virus infections
感知 RNA 病毒感染
  • DOI:
    10.1038/nchembio0107-20
  • 发表时间:
    2007-01-01
  • 期刊:
  • 影响因子:
    13.700
  • 作者:
    Christopher F Basler;Adolfo García-Sastre
  • 通讯作者:
    Adolfo García-Sastre

Christopher F Basler的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher F Basler', 18)}}的其他基金

Inhibitors of SARS-CoV-2 Polymerase
SARS-CoV-2 聚合酶抑制剂
  • 批准号:
    10514325
  • 财政年份:
    2022
  • 资助金额:
    $ 21.19万
  • 项目类别:
Understanding how the MERS Coronavirus protein ORF4b interactions with importin alpha modulate innate immunity
了解 MERS 冠状病毒蛋白 ORF4b 与 importin alpha 的相互作用如何调节先天免疫
  • 批准号:
    10289173
  • 财政年份:
    2021
  • 资助金额:
    $ 21.19万
  • 项目类别:
VPS34 inhibitors as SARS-CoV-2 antivirals
VPS34 抑制剂作为 SARS-CoV-2 抗病毒药物
  • 批准号:
    10534720
  • 财政年份:
    2021
  • 资助金额:
    $ 21.19万
  • 项目类别:
Understanding how the MERS Coronavirus protein ORF4b interactions with importin alpha modulate innate immunity
了解 MERS 冠状病毒蛋白 ORF4b 与 importin alpha 的相互作用如何调节先天免疫
  • 批准号:
    10438878
  • 财政年份:
    2021
  • 资助金额:
    $ 21.19万
  • 项目类别:
Small Molecule Inhibitors of Ebola Virus Polymerase Function
埃博拉病毒聚合酶功能的小分子抑制剂
  • 批准号:
    10534719
  • 财政年份:
    2021
  • 资助金额:
    $ 21.19万
  • 项目类别:
Understanding how the MERS Coronavirus protein ORF4b interactions with importin alpha modulate innate immunity
了解 MERS 冠状病毒蛋白 ORF4b 与 importin alpha 的相互作用如何调节先天免疫
  • 批准号:
    10536332
  • 财政年份:
    2021
  • 资助金额:
    $ 21.19万
  • 项目类别:
VPS34 inhibitors as SARS-CoV-2 antivirals
VPS34 抑制剂作为 SARS-CoV-2 抗病毒药物
  • 批准号:
    10238577
  • 财政年份:
    2021
  • 资助金额:
    $ 21.19万
  • 项目类别:
Intersection Between Viral Translation and Innate Immunity in the Context of Filovirus Infection
丝状病毒感染背景下病毒翻译与先天免疫之间的交叉
  • 批准号:
    10593400
  • 财政年份:
    2020
  • 资助金额:
    $ 21.19万
  • 项目类别:
Intersection Between Viral Translation and Innate Immunity in the Context of Filovirus Infection
丝状病毒感染背景下病毒翻译与先天免疫之间的交叉
  • 批准号:
    10425317
  • 财政年份:
    2020
  • 资助金额:
    $ 21.19万
  • 项目类别:
Intersection Between Viral Translation and Innate Immunity in the Context of Filovirus Infection
丝状病毒感染背景下病毒翻译与先天免疫之间的交叉
  • 批准号:
    10214516
  • 财政年份:
    2020
  • 资助金额:
    $ 21.19万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 21.19万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 21.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了